Skip Navigation

European Heart Journal 2001 22(20):1849-1851; doi:10.1053/euhj.2001.2764
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiowski, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiowski, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

The endothelin-type-A receptor in dilated cardiomyopathy: another key player?

W. Kiowski

Division of Cardiology, University Hospital, Zürich, Switzerland

References

  1. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995 Aug 9; 274 (6):462]. JAMA. 1995;273:1450–1456[Abstract/Free Full Text]
  2. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  3. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2001;101:558–569
  4. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1989;332:411–415
  5. Jahin H, Kobayashi S, Nishimura J, Kanaide H. Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Eur J Pharmacol. 1996;295:261–269[CrossRef][Web of Science][Medline]
  6. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434–2440[Abstract/Free Full Text]
  7. Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol. 2000;35:S69–73[CrossRef][Web of Science][Medline]
  8. Kiowski W, Sutsch G, Hunziker P. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736[CrossRef][Web of Science][Medline]
  9. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355[CrossRef][Medline]
  10. Mulder P, Richard V, Derumeaux G. Role of endogenous enothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–1982[Abstract/Free Full Text]
  11. Charron P, Tesson F, Poirier O. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. Eur Heart J. 1999;20:1587–1591[Abstract/Free Full Text]
  12. Herrmann SM, Schmidt-Petersen K, Pfeifer J. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2001;22:1948–1953[Abstract/Free Full Text]
  13. Liggett SB, Wagoner LE, Craft LL. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534–1539[Web of Science][Medline]
  14. Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med. 1997;75:867–875[CrossRef][Web of Science][Medline]
  15. Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation. 2001;103:1048–1050[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiowski, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiowski, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?